Latest News

Autolus Therapeutics aiming for NASDAQ IPO

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies. © Miltenyi Biotec


by tg

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price. 

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

The company is well-financed. Last September, Autolus added a US$80m Series C equity funding to US$96m raised in previous financing rounds led by Syncona Ltd., Woodford Investment Management, and Arix Bioscience plc.

Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I) a similar approach to approved CAR-T cell therapies from Novartis and Gilead Sciences, or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate however is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma.

Confo Therapeutics raise €30m in Series A financing

Confo Therapeutics has a dual business model. With revenues from drug discovery partnerships, the company has built a portfolio of first-in-class...

Researchers report how body fat affects imune cells

While the initial discovery of the presence of immune cells in fat was a surprising revelation to the field of immunology, it is now well-known that...

Polyneuron Pharma raise CHF22.5m in Series A financing

Polyneuron Pharmaceuticals AG develops glycopolymers that mimick epitopes of autoantibodies attacking the nervous system, providing a new...

AMR diagnostic specialist Gradientech raise $4.6m

Gradientech said it will use the proceeds from the rights issue for commercialisation of its QuickMIC™ diagnostic system. QuickMIC™ is a microfluidic...

Novartis acquires inflammasome blocker company IFM Tre

IFM Therapeutics LLC spin-out IFM Tre raised $31m in July following the acquisition of its mother company and its NRLP3-blocking cancer assets by...

US patent office grants Charpentier CRISPR patent

ERS Genomics Ltd, which was formed to provide broad access to the CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced...

AI improves protein manufacture

For unknown reasons, every production cell line or bacterial strain used to express therapeutic proteins recombinantly, has a preference for a...